렘데시비르 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Remdesivir Market size is expected to reach USD 47.00 Billion in 2034 from USD 5.23 Billion (2025) growing at a CAGR of 27.63% during 2026-2034.

The global Remdesivir market gained significant attention during the COVID-19 pandemic, as the antiviral drug became one of the first approved treatments for hospitalized patients. The surge in demand during the pandemic period led to rapid production scaling and global distribution. Even after the peak of the pandemic, the drug continues to be used in specific clinical scenarios, contributing to sustained, though moderated, market growth.

Growth drivers include the ongoing need for effective antiviral treatments and preparedness for future viral outbreaks. Healthcare systems continue to stockpile antiviral drugs like Remdesivir as part of emergency response strategies. Additionally, research into its potential applications for other viral infections may expand its use. Government support and collaborations with pharmaceutical companies have also played a role in maintaining market stability.

In the future, the Remdesivir market is expected to stabilize as COVID-19 cases decline globally. However, its role in pandemic preparedness and antiviral treatment protocols will sustain demand. Continued clinical research and potential formulation improvements could enhance its applicability. The market may also benefit from advancements in antiviral drug development, ensuring readiness for emerging infectious diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Route of Administration

• Oral
• Intravenous

By Dosage Form

• Tablets
• Frozen Solution
• Lyophilized Solution

By Distribution Channel

• Hospitals
• Clinics
• Drug Stores/Pharmacies
• Online
• Other Distribution Channels

COMPANIES PROFILED

• Gilead Sciences Inc, BrightGene BioMedical Technology Co Ltd, Hainan Haiyao Co Ltd, Sichuan Kelun Pharmaceutical Co Ltd, Hunan Warrant Pharmaceutical, Cipla Limited, Pfizer Inc, Merck Co Inc, Cayman Chemical Company, Dr Reddys Laboratories Ltd, Inovio Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL REMDESIVIR MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Route Of Administration
• 4.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL REMDESIVIR MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Dosage Form
• 5.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Frozen Solution Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lyophilized Solution Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL REMDESIVIR MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Drug Stores/Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Online Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL REMDESIVIR MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Route Of Administration
  • 7.2.2 By Dosage Form
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Route Of Administration
  • 7.3.2 By Dosage Form
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Route Of Administration
  • 7.4.2 By Dosage Form
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Route Of Administration
  • 7.5.2 By Dosage Form
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Route Of Administration
  • 7.6.2 By Dosage Form
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL REMDESIVIR INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Gilead Sciences Inc
  • 9.2.2 BrightGene Bio-Medical Technology Co Ltd
  • 9.2.3 Hainan Haiyao Co. Ltd
  • 9.2.4 Sichuan Kelun Pharmaceutical Co. Ltd
  • 9.2.5 Hunan Warrant Pharmaceutical
  • 9.2.6 Cipla Limited
  • 9.2.7 Pfizer Inc
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 Cayman Chemical Company
  • 9.2.10 Dr Reddy's Laboratories Ltd
  • 9.2.11 Inovio Pharmaceuticals